MALDI-TOF Mass Defect Analysis for Peptide Data Quality
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating MALDI-TOF mass spectrometry data from biological samples face challenges in assessing data quality due to systematic errors in measured masses, lack of widely accepted benchmarks, and inefficiencies in correcting mass distortions.
Innovation Solution
A method is developed to evaluate mass spectrometry data by comparing measured mass defects with expected mass defects, using computer-aided visualization and calculations to assess data quality and correct signal distortions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional methods are used to correct mass distortions, then data quality can be improved, but the correction process is either too imprecise or too time-consuming
Solution Approach 1:
The patent applies preliminary action by pre-calculating and storing expected mass defects for peptide sequences in a database before actual mass spectrometry analysis. During measurement, the system directly compares measured mass defects against these pre-computed values, eliminating the need for time-consuming real-time correction calculations while maintaining high precision through the use of established peptide mass defect relationships
Solution Approach 2:
The patent implements feedback by systematically comparing measured mass defects with expected mass defects from the database, identifying deviations, and using this comparison to assess data quality and guide further analysis. This feedback mechanism enables rapid identification of systematic errors without requiring iterative correction processes
2Loss of information
If comprehensive data analysis is performed on MALDI-TOF mass spectrometry data, then information on proteomic structure is obtained, but objective assessment of data quality and accuracy becomes difficult due to data complexity
Solution Approach 1:
The patent extracts the critical quality assessment parameter (mass defect) from the complex mass spectrometry data and separates it for dedicated analysis. By focusing specifically on mass defect comparisons rather than attempting to assess all data dimensions simultaneously, the system enables objective quality evaluation while preserving complete proteomic information for further analysis
Solution Approach 2:
The patent introduces mass defect comparison as an intermediary metric between raw mass spectrometry data and final quality assessment. This intermediary approach simplifies the evaluation process by providing a concrete, measurable parameter (mass defect deviation) that objectively reflects data quality without requiring complex multi-dimensional analysis
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables objective assessment of data quality, identifies defective data, and corrects mass distortions, thereby improving the accuracy and reliability of peptide analysis in MALDI-TOF mass spectrometry.
Implementation Method 1
a biological tissue sample is coated with a matrix solution after suitable sample preparation and is subjected to laser bombardment in a vacuum. Biological macromolecules are thereby extracted from the tissue and ionized
Implementation Method 2
Biological macromolecules are thereby extracted from the tissue and ionized, typically with a single positive charge
Implementation Method 3
The ions are subsequently accelerated in an electric field and recorded by a detector. The m/z value, i.e. the mass-to-charge ratio of the molecule, can be determined from the time of flight
Data Source
AI summary
The invention relates to a method to evaluate mass spectrometry data for the analysis of peptides from biological samples, particularly MALDI-TOF mass spectrometry data, comprising the steps of: providing expected mass defects; determining measured mass defects, i.e. the mass defects resulting from the mass spectrometry data; and comparing the measured mass defects with the expected mass defects.